10th Trends in Medical Mycology 2021 (TIMM) 8-11 October,2021, Aberdeen, England, 8 - 11 October 2021, pp.233
andidemia in hematological malignancies and intensive care patients; 4-year retrospective analysis
Objective: Invasive fungal infections are common life-threatening diseases and major cause of morbidity, particularly in patients with hematologic malignancies and patients of intensive care , and Candida spp. is the most common isolated fungi in bloodstream. In this study, Candida species, risk factors and comorbidities were investigated retrospectively among patients with hematological malignancies and intensive care unit.
Methods: Between 2017 and 2020, 4-year hospital data were retrospectively analyzed and recorded. The patients' age, gender, primary diseases, comorbidities, and development time of candidemia were evaluated.
Results: Acute leukemia, lymphoma, or myelodysplastic syndrome are the most common hematological malignancies associated with candidemia, while among ICU patients solid tumors and transplant has the majority of candidemia cases. Our results show that non-albicans candidemia is dominant among hematological malignancy patients and intensive care patients. While all patients with hematologic malignancies had non-albicans candidemia, this rate was 72.5% in intensive care patients. Candida glabrata was the most common isolate in both group. (Table). The results are summarized in the table.
Hematological malignancies patients
Primary diagnosis (9)
Primary diagnosis (29)
Solid organ malignancy
Day of hospital stay until candidemia (mean)
22,7 days (11-34 days)
22,8 days (7-95 days)
Conclusions: Candidemia is an emerging and important problem in intensive care unit patients and patients with hematological malignancies. Non-albicans Candida species are the major cause of candidemia, as determined in our study.